GlobalData revenue rises 4%, so why has DATA stock crashed more than 20%?

GlobalData Plc (LSE: DATA) suffered one of the sharpest London-listed results-day sell-offs on September 14 after the information-services company warned that full-year adjusted EBITDA would fall below market expectations as weaker underlying revenue growth collides with continued investment. First-half reported revenue increased 4% to £162.9 million and adjusted EBITDA rose 5% to £54.8 million, but those headline gains concealed underlying revenue growth of just 1% and effectively flat underlying adjusted EBITDA. Delayed London Stock Exchange data showed GlobalData shares around 56.8p during the session, down approximately 20.7%, reducing the company’s market capitalisation to roughly £371 million.

The severity of the reaction reflects more than a modest guidance change. GlobalData had already told investors in July that FY26 adjusted EBITDA was likely to sit toward the lower end of expectations and had specifically pointed to September 14 for more detail on its value-creation plans. Today’s statement went further, saying subdued underlying revenue growth and targeted second-half investment mean adjusted EBITDA is now expected to be below market expectations, while full-year underlying revenue growth is likely to be toward the lower end of the expected range.

Why did GlobalData shares collapse when reported revenue and adjusted EBITDA were still growing?

The problem lies in the quality of the reported growth. Recent acquisitions, principally Stylus and Cambridge Healthcare Research, contributed £7.9 million of year-on-year revenue growth, while a £3.3 million accounting adjustment associated with complimentary periods also benefited the reported figure. Foreign exchange reduced revenue by £3.4 million, and after adjusting for acquisitions, currency, the complimentary-period effect and disrupted events, underlying revenue growth was only 1%.

Adjusted EBITDA tells a similar story. The headline figure increased from £52.1 million to £54.8 million and the reported margin improved from 33% to 34%, but underlying adjusted EBITDA was £51.9 million compared with £52.1 million a year earlier. The £3.3 million complimentary-period revenue adjustment provided a one-off benefit, which means investors looking past the statutory presentation are seeing a core business whose profit growth has essentially stalled.

That distinction matters enormously for an information-services company whose valuation has historically depended on recurring subscription economics and scalable organic growth. Subscription revenue still increased 6% and represented 76% of total revenue, while value renewal rates for larger customers improved to 91%. However, GlobalData itself identified reducing churn and increasing volume renewal as major levers for organic growth, reinforcing the idea that acquisition activity cannot indefinitely substitute for faster underlying expansion.

Has GlobalData spent heavily on acquisitions without generating enough organic growth?

Since launching its Growth Transformation Plan in January 2024, GlobalData has completed seven acquisitions and invested more than £132 million to expand its proprietary data and competitive-intelligence capabilities. The portfolio includes BTMI, LinkUp, Celent, Deallus, AI Palette, Stylus and Cambridge Healthcare Research, with the latter acquired in April 2026 for £21.3 million in cash plus a £0.7 million loan note.

Cambridge Healthcare Research contributed £4.2 million of revenue between acquisition and June 30 but only £0.1 million of profit before tax during that period. That should not be treated as a definitive indication of long-term acquisition economics because integration is at an early stage, but it illustrates why investors increasingly need proof that GlobalData’s capital deployment can generate faster earnings growth rather than simply enlarge reported revenue.

The company’s medium-term ambition remains to accelerate underlying revenue growth and eventually recover adjusted EBITDA margins toward 40%. The market’s September 14 reaction suggests investors are no longer prepared to capitalise that ambition generously before the evidence arrives. A transformation strategy can create considerable value when acquisitions deepen customer relationships and expand cross-selling, but it becomes more difficult to defend if underlying growth remains around low single digits while margins require additional investment.

Should investors worry about GlobalData’s £133 million net bank debt?

GlobalData’s balance-sheet profile has changed materially. Net bank debt stood at £133 million at June 30 compared with £16.8 million a year earlier, while borrowings increased to £181 million from £76.8 million and cash declined to £48 million from £60 million. Last-12-month adjusted EBITDA was £112.9 million, putting reported net bank debt leverage at about 1.2 times.

That leverage ratio is not extreme for a subscription-heavy information business, but the direction deserves attention because GlobalData has simultaneously been acquiring companies and returning significant amounts of capital to shareholders. During H1, net M&A cash expenditure reached £21.7 million, £18.6 million was spent acquiring shares for cancellation and £8.5 million went to dividends. Free cash flow fell 27% to £31.3 million, while operating cash flow declined to £50.8 million from £66.1 million.

GlobalData subsequently completed another £30 million tender offer, taking total capital returned during FY26 to more than £49 million, while retaining the 0.3p interim dividend. The capital return can support per-share metrics by reducing the number of shares outstanding, but investors will increasingly compare the benefit of buybacks with the opportunity cost of higher borrowing when underlying EBITDA growth remains weak.

What would need to change for GlobalData shares to recover from the September 14 sell-off?

The most important evidence would be a meaningful reacceleration in underlying revenue rather than another period in which acquisitions create most of the reported growth. Contracted forward revenue increased 4% to £163.3 million, providing useful visibility, but underlying contracted forward revenue growth was much more modest. Investors will therefore want to see better customer retention, improved sales productivity and stronger organic expansion across the market-led divisions.

Margin development is the second test. Management is deliberately investing during H2 and argues that stronger revenue growth should eventually support a measured recovery toward a roughly 40% adjusted EBITDA margin. The market appears willing to tolerate investment, but September 14 demonstrates that it will not tolerate indefinitely postponing the earnings payoff.

The roughly 21% intraday share-price fall should not be treated as a settled closing verdict, because the London session remained open when the price was checked. It nevertheless represents a powerful repricing of expectations. GlobalData spent the past several years building a larger information-services platform; investors are now asking whether the next stage can deliver substantially better organic returns from what has already been assembled.